Brief: Immunovia Sees Modest Revenue Growth For 2023

Immunovia AB (publ)

23/05/2023 08:27

May 23 (Reuters) - Immunovia AB (publ)  IMMNOV.ST :
    * REVENUE GROWTH WILL BE MODEST IN 2023 AS MOST OF OUR TESTS
WILL
STILL BE PATIENT PAID, AND MANY OF THESE TESTS WILL BE OFFERED
AT DISCOUNT BASED ON PATIENT'S ABILITY TO PAY
    * DURING H2 OF 2023 WE EXPECT TO ANNOUNCE SPECIFIC
COLLABORATION
AGREEMENTS ON CLINICAL STUDIES WITH LEADING HEALTH CARE SYSTEMS,
RESEARCH CONSORTIA

Source text for Eikon:  ID:nWkr7GtRYP 
Further company coverage:  IMMNOV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))